Clinical Trial Update: A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 study evaluating the 12-month safety of the combination of aliskiren and hydrochlorothiazide in hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)
• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED